N/A N=9,707 Nasopharyngeal Streptococcus Pneumoniae Carriage
Streptococcus Pneumoniae Infections
Primary: Percentage of Participants With Carriage of Streptococcus Pneumoniae in Nasopharynx — 12.6 Percentage of Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=8,790 Streptococcus Pneumonia: Effects of PCV13 on Pneumococcal Carriage
Nasopharyngeal Carriage of S. Pneumoniae
Primary: Nasopharngeal Colonization With PCV13 S. Pneumoniae — 20; 31; 166; 137 Participants — p=<0.05
N/A N=3,641 Prevalence of Nasopharyngeal Carriage of Streptococcus Pneumoniae in Healthy Children of 12-18 Months in 6 Cities, China
Streptococcus Pneumoniae Infections
Primary: Percentage of Participants With Nasopharyngeal Carriage of Streptococcus Pneumoniae — 12.5; 7.2; 16.6; 9.3 percentage of participants
Phase 1 N=42 Phase I Safety Trial of Streptococcus Pneumoniae Whole Cell Vaccine (SPWCV) + Alum in Healthy Adults
Pneumococcal Vaccines
Primary: Unsolicited Adverse Event Reports — 7; 6; 5; 6 participants
Phase 3 N=181 Comparing Two Pneumococcal Vaccines in Adults With Chronic Obstructive Pulmonary Disease
Pulmonary Disease, Chronic Obstructive
Primary: Serotype Opsonization Titers — 10.85; 12.63; 132.51; 908.23 titers
N/A N=297 Nasopharyngeal Carriage Study in Healthy Kenyan Toddlers
Pneumococcal Disease
Primary: Prevalence of Streptococcus Pneumoniae in Nasopharynx — 76; 43; 86; 46 Participants
Phase 3 N=1,866 Study Evaluating the Impact of a 13-valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Colonization
Pneumococcal Infections
Primary: Percentage of Participants With a New Acquisition of Serotype 6A' (6A + 6C) or 19A Combined 1 Month After the Infant Series to 24 Months of Age — 20.0; 36.0 percentage…
N/A N=521 Pneumococcal Nasopharyngeal and Oropharyngeal Carriage in Adults
Preference, Patient
Primary: Prevalence — 16 Participants
Phase 4 N=70 Safety and Immunogenicity of Sequential Pneumococcal Immunization in Preschool Asthmatics
Asthma
Primary: Immunogenicity of Pneumococcal Vaccination — 0.05; 0.05 [µg/ml]
Phase 4 N=84,496 Study Evaluating the Effiacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in Adults
Pneumonia, Pneumococcal · Pneumococcal Infections · 13-valent Pneumococcal Vaccine
Primary: Number of Participants With First Episode of Confirmed Vaccine-type Community-acquired Pneumonia (VT-CAP) — 49; 90 participants — p=0.0006
Phase 3 N=1,160 Study Evaluating Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine With Influenza Vaccine in Adults
Pneumococcal Infections
Primary: TIV Comparisons: Percentage of Participants Achieving at Least a 4-fold Increase in the Titer of the Standard Hemagglutination Inhibition Assay (HAI) — 80.3; 78.6; 58.0…
N/A N=186 Immunity to Serotype 19A Streptococcus Pneumoniae in Children Vaccinated With PCV10
Pneumococcal Infections
Primary: Persistence of Humoral Immunity Following PCV10 Vaccination — 0.32; 0.35 micrograms per ml
Phase 3 N=41,181 Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disease
Infections, Streptococcal · Streptococcus Pneumoniae
Primary: Person Year Rate as Regards Subjects With Culture-confirmed IPD Due to Any of the 10 Pneumococcal Vaccine Serotypes. In Children Starting Vaccination Within 7 Months of…
N/A N=66 Bacterial Pneumonia Score (BPS) Guided Antibiotic Use in Children With Pneumonia and Pneumococcal Vaccine
Community Acquired Pneumonia
Primary: Use of Antibiotics in Each Group — 9; 21 participants — p=0.01
Phase 3 N=89 Immune Response In Children Revaccinated With Pneumococcal Conjugate Vaccine
Invasive Pneumococcal Disease
Primary: Percentage of Participants Achieving a Predefined Serotype-specific Immunoglobulin G (IgG) Antibody Concentration Greater Than or Equal to ( ≥) 0.35 Micrograms Per…
Phase 2 N=460 Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine in Healthy Infants
Pneumococcal Infections
Primary: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 1 — 24.9; 25.4; 22.3; 23.7 percentage of participants
Phase 2 N=444 Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age
Pneumococcal Infections
Primary: Percentage of Participants With Local Reactions Within 10 Days After Vaccination 1 — 7.3; 3.6; 3.6; 3.2 percentage of participants
Phase 2 N=750 Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years.
Pneumococcal Immunization
Primary: Geometric Mean Titers (GMTs) of Pneumococcal Serotypes Using Serotype-Specific MOPA — 128; 127; 158; 254 Titer
Phase 3 N=3,902 Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults
Pneumococcal Disease
Primary: Percentage of Participants With Local Reactions Within 10 Days After Vaccination in All Cohorts — 7.3; 6.2; 8.2; 5.4 percentage of participants
Phase 3 N=23,738 COMPAS (Clinical Otitis Media & Pneumonia Study): Pneumonia & Acute Otitis Media (AOM ) Efficacy Study of the Pneumococcal Conjugate Vaccine
Infections, Streptococcal
Primary: Number of Subjects With a First Episode Reported of Bacterial Community Acquired Pneumoniae (B-CAP) — 240; 304 Subjects
Phase 3 N=324 13-valent Pneumococcal Conjugate Vaccine Study in Adults => 50 Years of Age in Mexico
Pneumococcal Infections
Primary: Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) 1 Month After Vaccination — 120; 84; 88; 89 titer
Phase 3 N=251 Study to Evaluate 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) Vaccine Followed by 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients
Vaccines, Pneumococcal Conjugate Vaccine
Primary: Geometric Mean Fold Rise (GMFR) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody From Before 13vPnC Dose 1 to 1 Month After 13vPnC Dose 3 in All…
Phase 2 N=630 A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal Vaccine
Pneumonia, Bacterial · Healthy Volunteers · Pneumococcal Disease
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs), [Stage 1, Group 1] — 11; 5; 5; 5 Participants
N/A N=1,821 PCV13 Effectiveness Study Against Hospitalised VT Pneumococcal CAP in Adults 60 Years and Older
Community Acquired Pneumonia (CAP)
Primary: Number of Participants Categorized as Cases and Controls to Determine Vaccine Effectiveness (VE) of PCV13 Against Hospitalized VT CAP: Overall — 105; 1407 Participants…
Phase 3 N=806 Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine
Infections, Streptococcal
Primary: Number of Subjects Reporting Rectal Temperature Above (>) 39.0 Degrees Celsius (°C) — 31; 6; 30; 13 Participants
Phase 3 N=158 Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Children With Sickle Cell Disease
Pneumococcal Conjugate Vaccine
Primary: Geometric Mean Fold Rise (GMFR) in Serotype-Specific Pneumococcal Immunoglobulin G (IgG) From 1 Month After 13vPnC Dose 1 to 1 Month After 13vPnC Dose 2 — 0.75; 0.89…
Phase 3 N=2,068 Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults
Pneumococcal Infections
Primary: Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) 1 Month After Vaccination 1 — 146; 104; 200; 353 titer
Phase 4 N=25 Study Response of 13-valent Conjugate Pneumococcal Vaccine in Patients With End Stage Renal Disease
End Stage Renal Disease
Primary: Change From Baseline in Antibody Concentrations After 13-valent Conjugate Pneumococcal Vaccination in in Patients 50 Years or Older With End Stage Renal Disease on…
Phase 3 N=262 Study Evaluating Antibody Response Of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) 24 Months After Toddler Dose.
13-valent Pneumococcal Vaccine · Immunization · Safety
Primary: Serotype-specific Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentration (GMC) 1 Month After Single Dose of 13 Valent Pneumococcal Conjugate (13vPnC) Vaccine…
Phase 3 N=1,053 Study Evaluating Safety of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Elderly Subjects
Pneumococcal Infections
Primary: Percentage of Participants With Pre-specified Local Reactions — 14.3; 12.6; 6.5; 1.1 Percentage of Participants